Data PROpel Lynparza To Potential Prostate Cancer Megablockbuster
Combo Of PARP Inhibitor And J&J's Zytiga Delays Progression In All-Comers
Executive Summary
The Phase III PROpel study has shown that a combination of AstraZeneca's Lynparza and Johnson & Johnson's Zytiga significantly delayed disease progression as a first-line treatment for men with metastatic castration-resistant prostate cancer.
You may also be interested in...
Akeega Approval Means Three-Way PARP/Anti-Androgen Race In Prostate Cancer Is On
Despite the advantage of a single pill, the J&J drug could have the potential disadvantage of a narrower label in both the US and EU and Lynparza/Zytiga’s potentially higher efficacy.
Pfizer Scores Broad Label For Talzenna/Xtandi In Valuable First-Line Prostate Cancer Indication
The FDA approved the combination for patients with HRR gene-mutated disease, giving it a broader label than the BRCA-mutation label that AstraZeneca/Merck got for Lynparza/Zytiga.
AstraZeneca’s Lynparza Adds Narrow Prostate Cancer Indication
AstraZeneca had hoped data from Phase III PROpel would lead to an all-comers indication in first-line, metastatic castration-resistant prostate cancer, but new indication is limited to BRCA mutations.